Stay updated on Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Sign up to get notified when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.

Latest updates to the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedA new revision label 'Revision: v3.5.3' has been added, replacing the previous 'Revision: v3.5.2'. This metadata update does not alter the study details, eligibility criteria, or any participant-facing information.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedThe site revision was updated from v3.5.0 to v3.5.2. No visible changes to study details or navigation.SummaryDifference0.1%

- Check47 days agoChange DetectedAdded the term 'Mucopolysaccharidosis, MPS-II' and removed 'Mucopolysaccharidosis type 2' from the study's glossary/keywords.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision: v3.5.0 added and v3.4.3 removed.SummaryDifference0.1%

- Check61 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check90 days agoChange DetectedRevision: v3.4.2 was added to the page. The funding-lapse/open-status notice and the previous Revision: v3.4.1 entry were removed.SummaryDifference0.5%

Stay in the know with updates to Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.